X0M1 Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.80 |
52 Week High | US$26.20 |
52 Week Low | US$12.70 |
Beta | 0.93 |
11 Month Change | 25.24% |
3 Month Change | 6.61% |
1 Year Change | 80.42% |
33 Year Change | -5.84% |
5 Year Change | 55.29% |
Change since IPO | -73.94% |
Recent News & Updates
Recent updates
Shareholder Returns
X0M1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 4.9% | -1.2% | -0.2% |
1Y | 80.4% | -19.8% | 2.0% |
Return vs Industry: X0M1 exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: X0M1 exceeded the German Market which returned 1.9% over the past year.
Price Volatility
X0M1 volatility | |
---|---|
X0M1 Average Weekly Movement | 8.8% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 4.6% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: X0M1 has not had significant price volatility in the past 3 months.
Volatility Over Time: X0M1's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
X0M1 fundamental statistics | |
---|---|
Market cap | €306.66m |
Earnings (TTM) | -€41.55m |
Revenue (TTM) | €5.36m |
57.8x
P/S Ratio-7.5x
P/E RatioIs X0M1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
X0M1 income statement (TTM) | |
---|---|
Revenue | US$5.81m |
Cost of Revenue | US$122.00k |
Gross Profit | US$5.69m |
Other Expenses | US$50.77m |
Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.87 |
Gross Margin | 97.90% |
Net Profit Margin | -775.86% |
Debt/Equity Ratio | 146.6% |
How did X0M1 perform over the long term?
See historical performance and comparison